All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What advances have there been in biomarkers for AML?

During the 2021 ASCO Annual Meeting, the AML Hub spoke with Chris Hourigan, National Institutes of Health, Bethesda, US. We asked, What advances have there been in biomarkers for AML?

What advances have there been in biomarkers for AML?

Hourigan summarises three abstracts from ASCO, including MRD testing for risk stratification, using a 'mechanistic hubris' that moves past using single mutations, and finally, understanding the host microenvironment instead of solely focusing on leukemia biology.

 

Share:
More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox